Evidence map›Paper›PMID 35222856›Full record

ArticleIranian journal of microbiology2021

Activity of imipenem/relebactam on

Mervat El-Sayed Mashaly, Ghada El-Saeed Mashaly

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. JAC-antimicrobial resistance · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mervat El-Sayed MashalyDepartment of Clinical Pathology, Clinical Microbiology Unit, School of Medicine, Mansoura University, Mansoura, Egypt.
Ghada El-Saeed MashalyDepartment of Medical Microbiology and Immunology, School of Medicine, Mansoura University, Mansoura, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesImipenem/relebactam (IMP/R) is a newly FDA approved β-lactam/β-lactamase inhibitor combination. Relebactam ability to restore IMP activity could differ according to the cause of imipenem non-susceptibility. Therefore, we investigated the MATERIALS AND

methodsImipenem-nonsusceptible (IMP-NS)

resultsDuring the study period, 140 isolates of IMP-NS

conclusionRelebactam could restore IPM activity in KPC or AmpC-producing IMP/NS

Indexed as

Beta lactamasesImipenemKlebsiella pneumoniaePolymerase chain reactionRelebactam

Identifiers

PMID35222856
PMCPMC8816701
OpenAlexW4200081084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.